Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses

Rachel Kline; Thomas Wishart; Kevin  Mills; Wendy E  Heywood

doi:10.1016/j.bbadis.2019.06.012

Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses

Rachel Kline, Thomas Wishart, Kevin Mills, Wendy E Heywood

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, which generally present during childhood. With new treatments emerging on the horizon, there is a growing need to understand the specific disease mechanisms as well as identify prospective biomarkers for use to stratify patients and monitor treatment. The use of Omics technologies to NCLs have the potential to address this need. We discuss the recent use and outcomes of Omics to various forms of NCL including identification of interactomes, affected biological pathways and potential biomarker candidates. We also identify common
pathways affected in NCL across the reviewed studies.

Original language	English
Journal	BBA - Molecular Basis of Disease
Early online date	15 Jun 2019
DOIs	https://doi.org/10.1016/j.bbadis.2019.06.012
Publication status	E-pub ahead of print - 15 Jun 2019

Keywords / Materials (for Non-textual outputs)

Neuronal ceroid lipofuscinoses
Batten disease
CLN1-14
proteomics
metabolomics

Access to Document

10.1016/j.bbadis.2019.06.012

Revision 2 FINAL_Applying modern Omics to NCLs.docxAccepted author manuscript, 775 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Cite this

@article{94780090fb144cb0ab420efed59ae804,

title = "Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses",

abstract = "The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, which generally present during childhood. With new treatments emerging on the horizon, there is a growing need to understand the specific disease mechanisms as well as identify prospective biomarkers for use to stratify patients and monitor treatment. The use of Omics technologies to NCLs have the potential to address this need. We discuss the recent use and outcomes of Omics to various forms of NCL including identification of interactomes, affected biological pathways and potential biomarker candidates. We also identify commonpathways affected in NCL across the reviewed studies.",

keywords = "Neuronal ceroid lipofuscinoses, Batten disease, CLN1-14, proteomics, metabolomics",

author = "Rachel Kline and Thomas Wishart and Kevin Mills and Heywood, {Wendy E}",

year = "2019",

month = jun,

day = "15",

doi = "10.1016/j.bbadis.2019.06.012",

language = "English",

journal = "BBA - Molecular Basis of Disease",

issn = "0925-4439",

publisher = "Elsevier",

}

TY - JOUR

T1 - Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses

AU - Kline, Rachel

AU - Wishart, Thomas

AU - Mills, Kevin

AU - Heywood, Wendy E

PY - 2019/6/15

Y1 - 2019/6/15

N2 - The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, which generally present during childhood. With new treatments emerging on the horizon, there is a growing need to understand the specific disease mechanisms as well as identify prospective biomarkers for use to stratify patients and monitor treatment. The use of Omics technologies to NCLs have the potential to address this need. We discuss the recent use and outcomes of Omics to various forms of NCL including identification of interactomes, affected biological pathways and potential biomarker candidates. We also identify commonpathways affected in NCL across the reviewed studies.

AB - The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, which generally present during childhood. With new treatments emerging on the horizon, there is a growing need to understand the specific disease mechanisms as well as identify prospective biomarkers for use to stratify patients and monitor treatment. The use of Omics technologies to NCLs have the potential to address this need. We discuss the recent use and outcomes of Omics to various forms of NCL including identification of interactomes, affected biological pathways and potential biomarker candidates. We also identify commonpathways affected in NCL across the reviewed studies.

KW - Neuronal ceroid lipofuscinoses

KW - Batten disease

KW - CLN1-14

KW - proteomics

KW - metabolomics

U2 - 10.1016/j.bbadis.2019.06.012

DO - 10.1016/j.bbadis.2019.06.012

M3 - Article

SN - 0925-4439

JO - BBA - Molecular Basis of Disease

JF - BBA - Molecular Basis of Disease

ER -

Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this